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In this brief opinion article, we briefly summarized evidence that cellular phosphate 
burden from phosphate toxicity is a pathophysiological determinant of cancer cell 
growth. Tumor cells express more phosphate cotransporters and store more inorganic 
phosphate than normal cells, and dysregulated phosphate homeostasis is associated 
with the genesis of various human tumors. High dietary phosphate consumption causes 
the growth of lung and skin tumors in experimental animal models. Experimental studies 
show that excessive phosphate burden induces growth-promoting cell signaling, 
stimulates neovascularization, and is associated with chromosome instability and 
metastasis. Studies have also shown phosphate is a mitogenic factor that affects 
various tumor cell growth. Among epidemiological evidence linking phosphorus and 
tumor formation, the Health Professionals Follow-Up Study found that high dietary 
phosphorus levels were independently associated with lethal and high-grade prostate 
cancer. Further research is needed to determine how excessive dietary phosphate 
consumption influences initiation and promotion of tumorigenesis, and to elucidate 
prognostic benefits of reducing phosphate burden to decrease tumor cell growth and 
delay metastatic progression.  The results of such studies could provide the basis for 

















The annual global burden of cancer is projected to increase to 21.6 million new cancer 
cases in the year 2030, a 53 percent increase from 2012 which is partially linked to 
increasing Westernization of lifestyle [1]. Also, increased life expectancy may also 
contribute to such a surge, as advanced age is an important risk factor for cancer 
development. Food and diet are considered important determinants of cancer, but the 
causal mechanisms are not fully understood [2]. Many substances identified as 
carcinogens in vitro do not always lead to tumor formation in vivo [3], implying that 
additional growth-promoting factors may be involved in tumorigenesis. In addition to 
excessive consumption of certain micronutrients that promote unwanted cellular 
replication, the possibility exists that reduced levels of certain factors and 
micronutrients, like magnesium, iron, zinc could either promote excessive cellular 
proliferation or facilitate DNA damage [4-6]. 
A hallmark of cancer is that cancer cells are self-sufficient in growth-promoting 
signals, enabling tumorigenesis to progress autonomously without exogenous stimuli 
[7]; yet, there is evidence that cancer growth is influenced by exogenous nutritional 
factors. In this brief opinion article, we will focus on the adverse effects of phosphate 
toxicity on tumorigenesis. Of clinical significance, after following cases for 24 years in 
the Health Professionals Follow-Up Study, high levels of dietary phosphorus were found 
to be independently associated with lethal and high-grade prostate cancer [8]. Milk and 
dairy products contribute the high percentage of phosphorus intake in the American diet 
[9], and Newmark and Heaney proposed that phosphate from dairy products is a risk 















physicians and Swedish males [10]. Three glasses of milk consumed a day compared 
to one glass increased cancer mortality in Swedish women by 44% (hazard ratio 1.44, 
95% confidence interval 1.23 to 1.69) [11].  
In addition, in a mouse model of hepatocellular carcinoma which was induced by 
the hepatitis B virus (HBV) transfection, hepatic tumor was formed in a dose-dependent 
manner by feeding these mice with higher concentrations of the milk protein casein [12]; 
the investigators also reported that mice fed with 6% dietary casein had approximately 
75% fewer occurrences of tumors compared to mice fed with 22% dietary casein[12]. 
More importantly, when the reduced-casein dietary intervention was provided, even 
after tumor formation in these HBV-transfected mice, the intervention resulted in 
significant inhibition of tumor growth [12]. Similar observations were also noted in other 
studies; for instance, restricted casein feeding is linked to tumor growth inhibition in 
xenograft models of human breast and prostate cancer [13]. Of important relevance, 
casein is a phosphoprotein, rich in phosphorus; casein has been shown to increase the 
phosphorus content of laboratory rodent diets by as much as 50% [14].  
In 1996, Schipper et al. proposed that cancer evolves from dysregulated 
metabolic control pathways rather than from autonomous growth of cells, and the 
researchers further proposed that this metabolic dysregulation process may be 
reversible [15]; for instance, eradication of Helicobacter pylori infection with reduced 
immunoinflammatory stimulus can lead to clinical and genetic reversibility of gastric 
lymphoma and carcinoma [16, 17]. Furthermore, the potential may exist to regulate 
cancer cell growth and progression by reversing the dysregulation of phosphate 















phosphate burden, associated with dysregulated phosphate metabolism, acts as a 
growth-promoting determinant in various human and experimental models of tumors. 
Some of the strongest evidence includes the role of excess dietary phosphate in 
stimulating cancer growth through cell signaling within the phosphoinositide 3-kinase 
(PI3K) pathway [18]. Other dcumentation includes the role of a phosphate-rich 
microenvironment in promoting cancer cell metastasis [19], clinical associations of 
elevated serum phosphate in certain cancer patients [20], and findings of abnormal 
amounts of phosphate retention in tumors [21]. 
 
Regulation of Phosphate Homeostasis 
Phosphorus, an essential mineral, is ingested in food as natural phosphate compounds 
and chemical additives (polyphosphate, sodium phosphate, triphosphate, phosphoric 
acid, etc.) [9]. Organic phosphate compounds are digested to inorganic phosphate (Pi) 
in the form of dihydrogen phosphate (H2PO4) and mono-hydrogen phosphate (HPO4). 
Serum phosphate levels are highly sensitive to regulation by hormones that facilitate 
multiorgan crosstalk among bones, kidneys, parathyroid glands, and intestine (Figure 
1) [22-29].  Intestinal absorption of dietary phosphate intake is partly regulated by 
hormones such as bioactive vitamin D [1,25(OH)2D3], which increases active transport 
of phosphate by increasing intestinal expression of the type II sodium-phosphate co-
transporter, NaPi2b. Serum phosphate levels are regulated primarily by the kidneys; 
most renal reabsorption of phosphate occurs in the proximal tubules of the kidneys 
through the expression of sodium-phosphate cotransporters NaPi2a and NaPi2c. Bone 















of phosphorus from the hydroxyapatite bone matrix along with calcium during bone 
resorption. Bone also releases fibroblast growth factor 23 (FGF23), which is activated 
by its cofactor klotho to suppress renal phosphate transporters, decrease renal 
phosphate reabsorption, and increase urinary phosphate excretion [22-29]. FGF23 also 
suppresses bioactivation of vitamin D to decrease intestinal phosphate absorption and 
increase fecal phosphate excretion (Figure 1) [24, 30].  
Inorganic phosphate is incorporated into cells as phospholipids, adenosine 
triphosphate (ATP), nucleic acids, and other metabolites necessary for cell growth, 
function, and survival [22]. Despite the indispensable role of phosphate in normal 
cellular functions, the molecular regulation of intra- and extra-cellular phosphorus 
metabolism is not yet clearly defined. It is however evident from clinical and 
experimental studies that when the bone-kidney-intestinal axis fails to regulate optimal 
circulatory levels, hyperphosphatemia persists, and cellular phosphate burden produces 
a deleterious effect on various tissues and organs, ranging from vascular calcification to 
premature aging to tumor formation [31-35].  
 
Phosphate Transport and Tumorigenesis  
The abnormal morphology of the tumor cell is characterized by loss of uniformity of the 
individual cells, defects in the architectural orientation of the differentiating cells, 
abnormal cytoplasm, an enlarged and irregularly shaped nucleus (increased nuclear-to-
cytoplasmic ratios), and prominent nucleoli. Tumor cells stimulate vascular endothelial 
cell proliferation and form new capillaries through angiogenesis to support cancer cell 















with an irregular flow [36]. Of biological importance, neovascularization is an important 
component of the tumor microenvironment that can influence tumor cell function, 
growth, and behavior such as cell-matrix interactions, possibly through lamellipodia and 
filopodia formation.  
The membrane surface of cancer cells often contains filopodia and lamellipodia 
which provide adhesion and motility, sense the extracellular environment, and attract 
substrates [37, 38]. Of relevance, filopodia of osteoclast cells in bone seek out, break 
down, and transport calcium phosphate particles into the cell [39]; whether filopodia of 
soft tissue cells possess similar mineral ion transporting ability requires additional 
studies. Although biological behavior of mammalian cells and fungal cells are not 
always similar in response to an insult, it is however interesting to observe from a 
comparative biologic perspective that mycorrhiza fungi cells from a plant root system 
have hyphae that extend into the soil and are equipped with inorganic phosphate 
transporters (PiT) for cross-membrane intake and retention of orthophosphate such as 
H2PO4 [40, 41]. Evidence shows that additional cross-membrane transporters allow 
cancer cells to absorb greater amounts of phosphate from the tumor microenvironment. 
For example, ovarian carcinomas were found to overexpress sodium-phosphate co-
transporter NaPi2b, encoded by the SLC34A2 gene [42]. Increased expression of 
NaPi2b, more so than in normal tissue, was also found in thyroid, breast, and lung 
cancer [43], and fungal hyphae are prevalent in biopsies of precancerous epithelial 
lesions [44]. For instance, epithelial dysplasia and prevalence of fungal hyphae were 
significantly higher in leukoplakia (precancerous oral lesion) as compared to lichen 















increased prevalence of fungal hyphae [44]. Of clinical importance, the presence of 
fungal hyphae in potentially malignant lesions may be a useful indicator in predicting 
malignant transformation [44]. Furthermore, studies need to be conducted to determine 
whether phosphate transporter expression in tumor cells is limited to a certain 
carcinoma or it is a generalized phenomenon that may be present in sarcoma and other 
non-solid tumor cells, as well.    
The pointy, spiculated masses of some tumors were named “cancer” by 
Hippocrates, which described the tumors’ crab-leg shape [45-47]. Certain tumor cells 
extend into and move throughout the interstitium, equipped with overexpressed NaPi2b 
transporters capable of absorbing high levels of phosphorus from the tumor 
microenvironment. Inactivating the function of NaPi2b in the lung resulted in suppressed 
tumor growth, reduced cell proliferation and increased apoptotic cell death in a K-ras 
mutated murine model of lung cancer [48]. Furthermore, angiogenesis and 
neovascularization in breast cancer and lung cancer cells, in combination with human 
umbilical vascular endothelial cells, were stimulated in vitro by a high-phosphorus 
microenvironment [49]. High phosphate concentration increased gene expression of 
forkhead box protein C2 (FOXC2), osteopontin, and vascular endothelial growth factor 
in a dose-dependent manner; endothelial cell migration and tube formation were also 
observed in the high-phosphate microenvironment [49]; from the in vitro observations, 
the authors proposed that limiting the availability of phosphorus through reduced 
consumption could impair the growth of the ‘more metabolically active’ tumor cells while 
















Phosphate Sequestration and Tumorigenesis 
Inorganic phosphate, unbound to organic complexes, is mostly found in extracellular 
fluids, including the serum. Tumorigenesis develops in tissue containing cells with 
storage properties capable of supporting sequestration; tumors sequester more 
phosphorus isotope P32 than healthy tissue, which is why this radioactive isotope came 
into use in the early 20th century for tumor detection. Patients with advanced stages of 
malignant tumors were injected with P32 and examined after death; malignant cells 
within deceased patients were found to retain concentrations of P32 equal to or greater 
than concentrations in other highly metabolic tissue [50]. Malignant skin tumors also 
absorbed more P32 than benign tumors [51], greater concentrations of P32 were 
absorbed in leukemic tissue [52, 53], and mammary carcinoma, lymphoma, and 
lymphosarcoma tissue had a higher and faster uptake of P32 with longer retention than 
in normal tissue [54].  
Towards the end of the 20th century, magnetic resonance spectroscopy studies 
detected numerous organic phosphorus metabolites in tumor cells [55]. Of relevance, 
the amount of inorganic phosphate found in human cancer cells (HeLa cells) exceeded 
the phosphorus content of any of the organic phosphorus metabolites [55], verifying 
sequestration of excess inorganic phosphate in cancer cells. Compared to normal cells, 
up to twice as much inorganic phosphate was detected in cancer cells of the colon and 
lungs [21]. More recently a two-fold increase in inorganic phosphate concentration 
within the interstitial microenvironment of tumors was confirmed through in vivo 
assessment using advanced electron paramagnetic resonance profiling [19]. High 















increased breast cancer risk [56], and high levels of signalling phosphoprotein 
expression were found in ovarian tumors [57]. In addition to phosphate sequestration 
and tumorigenesis, hyperphosphatemia can directly activate certain gene expression 
through ERK1/2 and AKT signaling in epithelial and mesenchymal cells (e.g. 
fibroblasts), inducing epithelial-mesenchymal transformation and synthesis of matrix 
proteins [58, 59]; of particular importance, both epithelial-mesenchymal transformation 
and matrix production are important events for tumor growth and development. 
Additionally, hyperphosphatemia in animal models was shown to upregulate endothelin-
1 in endothelial cells, which increases reactive oxygen species and creates oxidative 
stress associated with inflammation, aging, and cancer [60]. Moreover, 
hyperphosphatemia can directly damage the endothelial cells by disrupting the 
mitochondrial membrane, generating reactive oxygen species, reducing nitric oxide 
production and inducing apoptosis, partly by activating the PKC pathway [61, 62], some 
of these events are also involved in tumorigenesis. 
 
Phosphate Toxicity and Tumorigenesis 
Cancer patients were observed to have over twice the mean value of phosphorus in 
their blood compared to patients without cancer: 7.80 (+2.24) mg/dL and 3.38 (+0.58) 
mg/dL, respectively (P<0.001) [20]. The researchers attributed elevated extracellular 
phosphate levels to the increased metabolic activity in cancer cells. In an examination of 
397,292 participants from the Swedish AMORIS study, Wulaningsih et al. found that 
high serum phosphorus levels were positively correlated with risk for cancers of the 















nonmelanoma skin cancer in women. However, high serum phosphate levels were 
negatively correlated with risk for breast and endometrial cancer in women, which the 
researchers suggested “reflects underlying estrogen levels” [63]. It is noted that 
estrogen is a mitogen that causes rapid cell division in reproductive tissue, and high 
serum phosphate levels are normally associated with rapid growth, as observed in 
infants and children. It should be mentioned that estrogen can suppress the expression 
of phosphate transporter, NaPi2a, in the kidneys, and enhance the production of FGF23 
in the bones [64]. However, this effect is related to estrogen treatment and may be 
influenced by other pharmacological factors. Nevertheless, the interplay between 
estrogen and phosphate levels as a contributor to tumor progression requires further 
carefully designed studies.  
Elevated serum phosphate levels at first diagnosis of lung cancer predicted 
patients’ disease stage and affected patient survival [65]. In a retrospective clinic-based 
cohort study of 1,241 colorectal cancer patients, post-operative hyperphosphatemia was 
negatively associated with patient survival [66].  In a similar line of observation, a study 
conducted on 110 patients with multiple myeloma found that high serum phosphate 
levels were significantly associated with shorter survival [67].  An unexpected finding in 
people who use heroin regularly had a normal serum phosphorus level compared to 
healthy subjects, and a retrospective analysis of 2,321 deceased heroin addicts from 
2001 to 2010, not a single recorded death from cancer was detected [68]. Of relevance, 
heroin users have dysfunctional eating patterns, eat infrequently, ingest inadequate 
amounts of food, consume low levels of proteins, and derive much of their calories from 















phosphorus and high renal phosphate reabsorption to maintain normal serum 
phosphate levels; although this hypothesis needs further experimental validation, as 
direct cause-and-effect relation is not yet established.   
A ketogenic diet was effective in reducing tumors in animal experiments [70], and 
the diet reduced progression of gliomas in brain cancer patients [71]. An analysis of the 
micronutrient content of a classic high-fat, low-carbohydrate ketogenic diet for children 
shows that the diet is low in phosphorus. For example, a sample ketogenic menu [72], 
modified in amounts for an adult, provides 2025 calories a day with a 4:1 ratio of fat to 
non-fat grams and only 599 mg of phosphorus, which is below the adult RDI of 700 mg. 
The low phosphate content of the classic ketogenic diet may be a determinant in 
reducing the size and progression of tumors, and further experimental investigations are 
warranted.  
 
Phosphate Dysregulation and Cancer Cell Signaling  
During stages of dysplasia and hyperplasia that may lead to cancer, atypical cells 
develop enlarged, irregularly shaped nucleoli that can upregulate ribosome biogenesis 
and increase production of ribosomal RNA (rRNA) [73]. The complex molecular 
machinery of the ribosome is composed of several distinct proteins and nucleic acids, 
and is vital for protein synthesis in living and proliferating cells. Rich in phosphorus, 
rRNA supports growth in rapidly dividing cells through protein biosynthesis, which is 
consistent with the tumor growth rate hypothesis [74]. Noting that phosphorus is a 
limiting factor in biological growth rate,  as well as being the least abundantly supplied 















calculation based on the growth rate hypothesis which predicted that reducing the 
tumor’s phosphorus intake in half will reduce three-quarters of the tumor size [75]. In an 
earlier study from 1955, phosphorus was found to play a key role in promoting 
precancerous tissue to cancer through increased phosphorus uptake into nuclear RNA, 
thus increasing cancer cell proliferation [76]. Of significant importance, the researchers 
found that carcinogenesis in precancerous tissue was delayed when phosphorus uptake 
by nuclear RNA was suppressed [76]. 
Similar to cytokines and various growth factors, phosphate can also induce 
cancer cell growth through various growth promoting signaling, including the PI3K 
pathway [18] (Figure 2); PI3K phosphorylates Akt (protein kinase B) to activate mTOR 
kinase, which in turn suppresses cell apoptosis and up-regulates synthesis of protein by 
phosphorylating important regulators of mRNA translation [77]. Of particular relevance, 
Jin et al. found that high dietary phosphate activated Akt phosphorylation, a key 
regulator of tumor growth, thus facilitating cap-dependent protein translation and 
increasing lung tumorigenesis in mice [78]. The researchers also found that high dietary 
phosphate suppressed phosphatase and tensin homolog (PTEN), a tumor suppressor 
phosphatase, and inorganic phosphate suppressed carboxyl-terminal modulator protein 
(CTMP), a negative regulator of Akt activity. Another signaling pathway associated with 
tumor growth is regulated by the GTP-binding protein N-ras. Camalier et al. found that a 
high-phosphorus diet activated N-ras and increased skin papilloma by around 50% in 
experimental animals [79]. 
Evidence also shows an association between high phosphate concentration and 















endocrine dysregulation, increased the risk of chromosome aberrations in the 
parathyroid glands of patients with hyperparathyroidism [80], and genotoxic effects from 
exposure to phosphate food additives were induced in lymphocytes [81]. Additionally, 
DNA damage is associated with chronic renal failure in patients, within whom phosphate 
metabolism is often dysregulated [82].   
Tumor cells contain self-digesting lysosomal proteases that are active during the 
catabolic process of autophagy and apoptosis; more so than in normal tissue [83]. 
These proteases interact with and modulate phosphorylating kinases in signaling 
pathways to lower cell proliferation in cancer [84]. Of relevance, high dietary phosphate, 
shown to increase phosphorylation of kinases in the Akt pathway of tumorigenesis [78], 
may increase tumorigenesis through the predominance of phosphorylating kinases over 
modulating proteases. This is further evidenced by apoptosis suppression after 
increased kinase phosphorylation during cross-talk among the signaling pathways [85, 
86]. The balance between phosphorylating kinases and modulating proteases helps 
explain why lower phosphorus diets, associated with fewer phosphorylating kinases, 
may increase the preponderance of proteases that reduce cancer cell proliferation. How 
such interaction between kinases and proteases may be influenced by the total body 
phosphate content needs additional studies.  
 Recent evidence has shown that phosphate starvation is sufficient to induce 
autophagy in eukaryotic yeast cells (Saccharomyces cerevisiae) [87]. The researchers 
found that phosphate starvation resulted in dephosphorylation of autophagy protein 
Atg13 which initiates the autophagy process. Whether such phenomenon in the yeast 















important to mention that Atg11 was also a necessary factor in phosphate starvation-
induced autophagy [87]. It is noteworthy that Atg 13 dephosphorylation is caused by 
inactivation of the TORC1 signaling pathway; a pathway which researchers have shown 
is responsive to phosphorus levels in cancer cells [87].  
 
Phosphate and Tumor Metastasis 
The “seed and soil” hypothesis of metastasis proposes that tumors spread through 
wandering rogue cancer cells in the blood and lymph; yet, corroboration of this and 
related hypotheses of metastasis are not always easy to demonstrate in an in vivo 
setup, and are beyond current technological capabilities [88]. Alternatively, Ramirez and 
Fiedler reported that a high concentration of inorganic phosphate plays a role in tumor 
cell behavior [89], and it is hypothesized that phosphate and perhaps associated factors 
released from bone during osteolysis could produce a microenvironment that facilitates 
bone metastasis in breast tumors by modulating the activity of cancer cells. Recently, 
researchers using in vivo electron paramagnetic resonance profiling with a specially 
developed probe found that interstitial inorganic phosphate concentration within the 
tumor microenvironment provided a marker that can distinguish highly metastatic 
tumors from non-metastatic tumors [19]. This is the first in vivo evidence suggesting that 
systemic phosphate toxicity may be an important determinant of metastasis. The 
pathobiological plausibility of this determinant is further supported by evidence of 
conditions linked to phosphate toxicity in cancer patients, discussed below. 
 Dysregulation of phosphate metabolism is associated with conditions such as 















including vascular calcification, which are often present as comorbidities in cancer 
patients. For example, various types of cancer is closely associated with CKD [90], 
bone disorders [91], and cardiovascular diseases [92]. CKD patients receiving dialysis 
to control hyperphosphatemia have a higher rate of comorbid cancers than the general 
population, including cancers of the bladder, kidney, liver, thyroid, tongue, cervix, as 
well as non-Hodgkin lymphoma and multiple myeloma [93]. Of relevance, 
paraneoplastic nephropathies are well-documented complications for numerous tumors, 
including lung tumors, gastrointestinal tumors and Hodgkin’s disease [94, 95].  
Moreover, the risk of epileptic seizures is significantly increased in cancer patients [96], 
and seizures occur in tumor lysis syndrome as excess phosphorus is released into the 
serum and causes secondary hypocalcemia [97]. Toxic conditions related to 
dysregulated phosphate metabolism, including malnutrition and systemic inflammation 
[98], are also seen in cachexia of terminal cancer patients [99]. As mentioned, patients 
with end-stage CKD receiving either dialysis or transplantation are at higher risk for 
developing a wide range of tumors, including of the lung and prostate [100-102]. More 
concerning is the documentation of increased risk for cancer in CKD patients, even at 
the early stages of the disease [103, 104]. Of clinical significance, phosphate toxicity is 
a major disease manifestation noted in patients with all stages of CKD; how phosphate 
toxicity promotes tumorigenesis and eventual metastasis in patients with CKD needs 
further clinical and experimental studies.  
 The enzyme alpha-klotho is an endocrine regulatory factor in phosphate 
homeostasis that has been linked to tumor suppression [105, 106]. Klotho acts as a 















The FGF23-klotho complex suppresses the expression and function of Na+-dependent 
phosphate co-transporters NaPi2a and NaPi2c in the renal tubules, thus reducing renal 
reabsorption and increasing phosphaturia. Klotho expression is reported to be reduced 
in many types of tumor tissues compared to corresponding normal tissues, including 
breast, pancreatic, liver, cervical, ovary, gastric, prostate, esophageal, rectal, colon, 
melanoma, and some lung cancer types [108]. Decreased klotho expression may be 
related to increased phosphate levels as clearly shown in earlier mouse genetic studies 
[34, 109-114], and in patients with a mutation in the Klotho gene [115]. In vitro studies 
also suggest that Klotho inhibits the Wnt/B-catenin pathway in human hepatocellular 
carcinoma [116], and the extracellular KL1 domain of the mouse Klotho protein, rather 
than the K2 domain, was found to actively suppress breast cancer cells [117]. From 
recently reported evidence, it appears more likely that the essential phosphate-
regulating factor klotho is a tumor suppressor gene, as well [118].  The expression of 
Klotho gene is shown to be suppressed by hypermethylation of DNA in various cancer 
cells, including cervical, colorectal, gastric and breast cancers [119-121], implicating 
that expression of Klotho may be closely associated with genesis of tumor in certain 
tissues and organs. As mentioned, Klotho can suppress cell proliferation and metastasis 
by inhibiting growth factor signaling such as insulin-like growth factor 1 (IGF-1) and 




In this brief opinion article, we summarized the evidence showing that experimental 















with lower levels of phosphate. Pathophysiological evidence indicates that tumors 
sequester excess levels of serum phosphorus while stimulating tumorigenesis, 
neovascularization, chromosome instability, and possibly metastasis (Figure 3). These 
findings are supported by additional clinical and epidemiological associations between 
high levels of dietary phosphate consumption, increased serum phosphate levels, 
tumorigenesis, and comorbidities in cancer patients. Of clinical importance, phosphate 
toxicity could be both cause (tumor-promoting factor) and consequences (cachexia) of 
tumorigenesis. Finally, we propose that cancer patients may receive therapeutic 
benefits upon referral to renal dietitians who are skilled in restricting patients’ dietary 
phosphorus intake, and we encourage further research of dietary phosphate 
manipulation in the initiation, promotion, progression, recovery, and prevention of 
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Total body phosphorus homeostasis is primarily maintained by a multi-organ cross-talk 
among parathyroid gland, intestine, kidney, and bone; intestinal absorption of dietary 
phosphate, renal reabsorption of ultrafiltrated phosphate in proximal tubular epithelial 
cells, and the shift of intracellular phosphate between extracellular and storage 
phosphate determine the phosphate homeostasis.  Of clinical importance, since less 
than 1% of total body phosphorus is extracellular, the serum phosphorus concentration 
does not truly reflect total body phosphorus content and is also a poor predictor of 


















Cancer cells respond to growth factors through a signaling pathway in which 
phosphoinositide 3-kinase (PI3K) phosphorylates Akt (protein kinase B) [18]. Akt 
activates mTOR kinase, which in turn can suppress apoptotic cell removal and induce 
cell proliferation [77]. High dietary phosphate was found to activate Akt 
phosphorylation, facilitating cap-dependent protein translation and increasing lung 
tumorigenesis in mice [78]. High dietary phosphate in mice also suppressed PTEN, a 





















Studies have shown that cellular phosphate burden can stimulate tumorigenesis [76], 
possibly by exerting mitogenic effects on tumor cells, promoting angiogenesis [49], 
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